Debiopharm and MSM to Collaborate on Novel Oncology Biologic
Debiopharm Group (Lausanne, Switzerland) and MSM Protein Technologies (MSM, Boston, MA) have entered into an exclusive agreement for the development and commercialization of Debio 0929, an antibody targeting a G protein-coupled receptor (GPCR), to be developed into a new oncology therapeutic drug.
Debiopharm Group (Lausanne, Switzerland), a global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and MSM Protein Technologies (MSM, Boston, MA), a human antibody drug discovery company, have entered into an exclusive agreement for the development and commercialization of Debio 0929, an antibody targeting a G protein-coupled receptor (GPCR), to be developed into a new oncology therapeutic drug.
GPCRs comprise a large protein family of transmembrane receptors that sense molecules outside the cell and activate inside signal transduction pathways and, ultimately, cellular responses. A G-protein is an intracellular membrane-associated protein, responsible for activating the signaling cascade. GPCRs are coupled to G-proteins. GPCRs are the largest, most versatile group of membrane receptors and also the most pharmaceutically important, because more than 30% of the low-molecular weight drugs currently on the market are targeting this kind of receptors.
Under the terms of the agreement, Debiopharm and MSM have formed a partnership to select antibodies against the GPCR. After completion of the discovery phase, MSM will grant Debiopharm a worldwide exclusive license for the development and commercialization of the antibody. MSM will retain marketing rights for Russia, the Ukraine, and several other countries in Eastern Europe and Asia. MSM will receive milestone payments from Debiopharm during the development of the product, and a share of royalties on net sales.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
